CA2692334A1 - Gaboxadol for treating depression and other affective disorders - Google Patents

Gaboxadol for treating depression and other affective disorders Download PDF

Info

Publication number
CA2692334A1
CA2692334A1 CA2692334A CA2692334A CA2692334A1 CA 2692334 A1 CA2692334 A1 CA 2692334A1 CA 2692334 A CA2692334 A CA 2692334A CA 2692334 A CA2692334 A CA 2692334A CA 2692334 A1 CA2692334 A1 CA 2692334A1
Authority
CA
Canada
Prior art keywords
gaboxadol
serotonin reuptake
serotonin
reuptake inhibitor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2692334A
Other languages
English (en)
French (fr)
Inventor
Connie Sanchez
Bjarke Ebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H. Lundbeck A/S
Connie Sanchez
Bjarke Ebert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2692334(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S, Connie Sanchez, Bjarke Ebert filed Critical H. Lundbeck A/S
Publication of CA2692334A1 publication Critical patent/CA2692334A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2692334A 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders Abandoned CA2692334A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07
DKPA200400016 2004-01-07
CA002529805A CA2529805A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002529805A Division CA2529805A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
CA2692334A1 true CA2692334A1 (en) 2004-12-29

Family

ID=58707228

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2692334A Abandoned CA2692334A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
CA002529805A Abandoned CA2529805A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002529805A Abandoned CA2529805A1 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Country Status (10)

Country Link
KR (1) KR20060025192A (es)
AR (1) AR047550A1 (es)
CA (2) CA2692334A1 (es)
CL (2) CL2004001607A1 (es)
EA (1) EA200600101A1 (es)
IS (1) IS8138A (es)
ME (2) ME00030B (es)
NO (1) NO20060229L (es)
RS (1) RS20050911A (es)
TW (1) TW200509918A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
TW200509918A (en) 2005-03-16
AR047550A1 (es) 2006-01-25
ME00030B (me) 2010-06-10
CL2004001607A1 (es) 2005-05-27
IS8138A (is) 2005-11-21
CA2529805A1 (en) 2004-12-29
KR20060025192A (ko) 2006-03-20
RS20050911A (en) 2007-08-03
NO20060229L (no) 2006-01-16
CL2010000166A1 (es) 2010-07-02
MEP1908A (xx) 2010-02-10
EA200600101A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
US20090203731A1 (en) Treatment of depression and other affective disorders
AU2004248890A1 (en) Gaboxadol for treating depression and other affective disorders
CN101448805B (zh) 抑郁障碍的治疗
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
ZA200509356B (en) Gaboxadol for treating depression and other affective disorders
MXPA06003393A (es) Tratamiento de trastornos neurologicos relacionados con alteraciones del sueno de movimientos oculares rapidos (rem) con antagonistas de receptor npy y5.
CA2692334A1 (en) Gaboxadol for treating depression and other affective disorders
AU2010252740A1 (en) Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
AU2004269858A1 (en) The combination of a serotonin reuptake inhibitor and Loxapine
US20070042014A1 (en) Combination of a serotonin reuptake inhibitor and loxapine
AU2004266057A1 (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
CA2537757A1 (en) The combination of a serotonin reuptake inhibitor and amoxapine
AU2004269857A1 (en) The combination of a serotonin reuptake inhibitor and Amoxapine
ZA200509588B (en) The combination of a serotonin reuptake inhibitors and agomelatine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead